N-acétyl-5-méthoxytryptamine

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• acute kidney injury [Insufficient Evidence]
• ADHD [Insufficient Evidence]
• age-related macular degeneration [Insufficient Evidence]
• athletic performance [Possibly Ineffective]
• atopic dermatitis (eczema) [Insufficient Evidence]
• autism spectrum disorder [Insufficient Evidence]
• benzodiazepine withdrawal [Likely Ineffective]
• bipolar disorder [Insufficient Evidence]
• BPH [Insufficient Evidence]
• bronchopulmonary dysplasia [Insufficient Evidence]
• CABG [Insufficient Evidence]
• cachexia [Possibly Ineffective]
• cancer, adjunct tx [Possibly Effective]
• cancer-related fatigue [Possibly Ineffective]
• cancer-related pain [Possibly Ineffective]
• chronic fatigue syndrome [Insufficient Evidence]
• cluster headache [Insufficient Evidence]
• cognitive impairment [Insufficient Evidence]
• colorectal CA [Insufficient Evidence]
• contraception [Insufficient Evidence]
• COPD [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• critical illness (trauma) [Possibly Ineffective]
• delayed sleep phase syndrome [Likely Effective]
• delirium [Insufficient Evidence]
• dementia [Possibly Ineffective]
• depression [Likely Ineffective]
• diabetes mellitus [Insufficient Evidence]
• diabetic neuropathy [Insufficient Evidence]
• dysmenorrhea [Insufficient Evidence]
• dyspepsia [Insufficient Evidence]
• emergence delirium [Possibly Effective]
• endometriosis [Insufficient Evidence]
• endotracheal intubation-related hemodynamic effects [Insufficient Evidence]
• epilepsy [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• GERD [Insufficient Evidence]
• H. pylori infection [Insufficient Evidence]
• heart failure [Insufficient Evidence]
• HTN [Possibly Effective]
• IBS [Insufficient Evidence]
• infertility [Possibly Ineffective]
• insomnia [Possibly Effective]
• ischemic reperfusion injury [Insufficient Evidence]
• jet lag [Possibly Effective]
• lung CA [Insufficient Evidence]
• melasma [Insufficient Evidence]
• menopausal sx [Insufficient Evidence]
• metabolic syndrome [Insufficient Evidence]
• MI [Insufficient Evidence]
• migraine prophylaxis [Possibly Effective]
• multiple sclerosis [Insufficient Evidence]
• neonatal encephalopathy [Insufficient Evidence]
• nocturnal enuresis [Insufficient Evidence]
• nonalcoholic fatty liver dz [Insufficient Evidence]
• non-24h sleep-wake disorder, blind pts [Likely Effective]
• obesity [Insufficient Evidence]
• oral mucositis, chemo-or XRT-related [Insufficient Evidence]
• osteopenia [Insufficient Evidence]
• osteoporosis [Insufficient Evidence]
• pain, acute [Insufficient Evidence]
• pain, chronic [Insufficient Evidence]
• periodontitis [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• postop nausea/vomiting [Insufficient Evidence]
• postop pain [Insufficient Evidence]
• postop recovery [Insufficient Evidence]
• postop sleep disturbance [Insufficient Evidence]
• postural tachycardia syndrome [Insufficient Evidence]
• pre-eclampsia [Insufficient Evidence]
• preop anxiety [Possibly Effective]
• preop sedation [Possibly Effective]
• prostate CA [Insufficient Evidence]
• pruritus [Insufficient Evidence]
• radiation dermatitis [Insufficient Evidence]
• REM sleep behavior disorder [Insufficient Evidence]
• renal failure [Insufficient Evidence]
• renal transplant [Insufficient Evidence]
• restless legs syndrome [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• sarcoidosis [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• seasonal affective disorder [Insufficient Evidence]
• sepsis [Insufficient Evidence]
• shift-work disorder [Possibly Ineffective]
• smoking cessation [Insufficient Evidence]
• stabbing headache [Insufficient Evidence]
• stress [Insufficient Evidence]
• sunburn [Possibly Effective]
• tardive dyskinesia [Insufficient Evidence]
• temporomandibular disorder [Possibly Effective]
• tension headache [Insufficient Evidence]
• thrombocytopenia, chemo-related [Possibly Effective]
• tinnitus [Insufficient Evidence]
• traumatic brain injury [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]
• xerostomia [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note, COVID-19

[no scientific data for COVID-19]

Info: see Herb & Supplement Remedy Use in COVID-19 Resources

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

acute kidney injury

[Insufficient Evidence]

Dose: 3-30 mg PO qd

ADHD, peds pts

[Insufficient Evidence]

Dose: 3-5 mg PO qhs

age-related macular degeneration

[Insufficient Evidence]

Dose: 3 mg PO qhs

atopic dermatitis, peds pts

[Insufficient Evidence]

Dose: 3-6 mg PO qhs

autism spectrum disorder, peds pts

[Insufficient Evidence]

Dose: 2-5 mg PO qhs; Info: prolonged-release product

bipolar disorder

[Insufficient Evidence]

Dose: 3 mg PO qhs

BPH

[Insufficient Evidence]

Dose: 2 mg PO qhs; Info: controlled-release product

bronchopulmonary dysplasia, peds pts

[Insufficient Evidence]

Dose: 5 mg/kg/day PO qd; Info: used in preterm neonates 27-32 wk gestation

CABG

[Insufficient Evidence]

Dose: 3 mg PO qhs; Info: may give night before and morning of surgery, then x3 days after surgery

cancer, adjunct tx

[Possibly Effective]

Dose: 10-40 mg PO qpm; Alt: 20 mg IM qd x2mo, then 10 mg PO qpm; Info: used w/ chemo, XRT, or interleukin-2 for solid tumors

chronic fatigue syndrome

[Insufficient Evidence]

Dose: 5 mg PO qpm; Alt: 1 mg PO qhs

cluster headache

[Insufficient Evidence]

Dose: 10 mg PO qpm x14 days

cognitive impairment

[Insufficient Evidence]

Dose: 10 mg PO qhs

COPD

[Insufficient Evidence]

Dose: 3 mg PO qd

COVID-19

[Insufficient Evidence]

Dose: 2-24 mg/day PO divided qd-qid; Info: 3 mg PO tid in pts w/ mild-moderate COVID-19; 5 mg PO bid in pts w/ severe COVID-19

delayed sleep phase syndrome, adult pts

[Likely Effective]

Dose: 0.3-5 mg PO qhs

delayed sleep phase syndrome, peds pts

[Likely Effective]

Dose: 1-6 mg PO qhs

delirium

[Insufficient Evidence]

Dose: 0.5-10 mg PO qd; Alt: 3 mg PO x2 before surgery, then 3 mg PO x2 after surgery; 50 mg/kg/dose PO x1

diabetes mellitus

[Insufficient Evidence]

Dose: 3-10 mg PO qd

diabetic neuropathy

[Insufficient Evidence]

Dose: 6 mg PO qhs; Start: 3 mg PO qhs x1wk; Info: used w/ pregabalin

dysmenorrhea

[Insufficient Evidence]

Dose: 10 mg PO qhs; Info: used during menstruation wk

dyspepsia

[Insufficient Evidence]

Dose: 5 mg PO qhs

emergence delirium, adult pts

[Possibly Effective]

Dose: 3-5 mg PO qd

emergence delirium, peds pts

[Possibly Effective]

Dose: 0.05-0.5 mg/kg/dose PO qd in pts 2-9 yo; Info: used w/ anxiolytic tx

endometriosis

[Insufficient Evidence]

Dose: 10 mg PO qd

endotracheal intubation-related hemodynamic effects

[Insufficient Evidence]

Dose: 6 mg PO x1 given 2h before anesthesia

epilepsy, adult pts

[Insufficient Evidence]

Dose: 3 mg PO qhs; Info: used w/ valproate

epilepsy, peds pts

[Insufficient Evidence]

Dose: 1.5-3 mg PO qhs in pts 2-15 yo; 10 mg PO qhs in pts 9 yo and older

fibromyalgia

[Insufficient Evidence]

Dose: 3-5 mg PO qhs

GERD

[Insufficient Evidence]

Dose: 3 mg PO qhs

H. pylori infection

[Insufficient Evidence]

Dose: 5 mg PO bid x21 days; Info used w/ standard tx

heart failure

[Insufficient Evidence]

Dose: 10 mg PO qpm

HTN

[Possibly Effective]

Dose: 2-24 mg PO qhs; Info: controlled-release product

IBS

[Insufficient Evidence]

Dose: 3 mg PO qhs; Alt: 3 mg PO qam and 3-5 mg PO qhs

insomnia, adult pts

[Possibly Effective]

Dose: 2-5 mg PO qhs given 30min to 2h before desired bedtime; Info: 2.5-5 mg PO qhs in pts w/ beta-blocker-induced insomnia; 1.5-10 mg PO qhs in pts w/ dementia; 3 mg PO qhs in pts w/ epilepsy or dialysis pts; 2-12 mg PO qhs in pts w/ asthma, bipolar disorder, cystic fibrosis, depression, schizophrenia, hospitalized pts, or post-op pts

insomnia, peds pts

[Possibly Effective]

Dose: 0.05-0.15 mg/kg/dose PO qhs given 30min before desired bedtime in pts 6-12 yo; Alt: 5 mg PO qhs given 30min before desired bedtime in pts 6-12 yo; Info: 3 mg PO qhs given 30-60min before desired bedtime in pts 3 mo-2 yo w/ epilepsy; 6-9 mg PO qhs given 30min before desired bedtime in pts 3-12 yo w/ epilepsy

ischemic reperfusion injury

[Insufficient Evidence]

Dose: 2-50 mg IV x1; Start: w/in 2.5-3.5h of ischemia onset

jet lag

[Possibly Effective]

Dose: 0.5-8 mg PO qhs; Start: day of arrival; Info: doses >5 mg rarely more effective

menopausal sx

[Insufficient Evidence]

Dose: 3 mg PO qhs

metabolic syndrome

[Insufficient Evidence]

Dose: 5 mg PO qhs

MI

[Insufficient Evidence]

Dose: 51.7 mcmol IV x1 immediately before PCI, then 8.6 mcmol IV x1 w/in 60sec after blood flow restoration

migraine prophylaxis, adult pts

[Possibly Effective]

Dose: 3-4 mg PO qhs

migraine prophylaxis, peds pts

[Possibly Effective]

Dose: 0.3 mg/kg/dose PO qhs; Info: for pts 5-15 yo

neonatal encephalopathy

[Insufficient Evidence]

Dose: 10 mg/kg/dose PO qd; Alt: 5 mg/kg/dose IV qd

nonalcoholic fatty liver dz

[Insufficient Evidence]

Dose: 6-18 mg PO qd

non-24h sleep-wake disorder, adult pts

[Likely Effective]

Dose: 0.5-10 mg PO qhs in blind pts

non-24h sleep-wake disorder, peds pts

[Likely Effective]

Dose: 0.5-4 mg PO qhs in blind pts

obesity

[Insufficient Evidence]

Dose: 3-10 mg PO qd

oral mucositis, chemo-or XRT-related

[Insufficient Evidence]

Dose: 20 mg PO qhs plus 10 mL of melatonin 0.2% oral gargle 15min before radiation; Alt: 10 mL of melatonin 3% gel mouthwash x2min before radiation

osteopenia

[Insufficient Evidence]

Dose: 3 mg PO qhs

pain, acute

[Insufficient Evidence]

Dose: 6 mg PO x1 given 2h before anesthesia

pain, chronic

[Insufficient Evidence]

Dose: 3-12 mg PO qd

periodontitis

[Insufficient Evidence]

Dose: 3-10 mg PO qd

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 2 mg PO qhs; Alt: 6 mg PO qd

postop pain

[Insufficient Evidence]

Dose: 1-10 mg PO qd x1-21 days; Start: usually night before surgery

postop recovery

[Insufficient Evidence]

Dose: 5 mg PO x1 given 90min before surgery; Info: extended-release product

postural tachycardia syndrome

[Insufficient Evidence]

Dose: 3 mg PO x1

pre-eclampsia

[Insufficient Evidence]

Dose: 10 mg PO tid; Info: sustained-release product

preop anxiety, adult pts

[Possibly Effective]

Dose: 3-10 mg PO x1 given 20-120min before surgery; Alt: 0.05-0.4 mg/kg/dose SL x1 given 20-120min before surgery

preop anxiety, peds pts

[Possibly Effective]

Dose: 0.05-0.5 mg/kg/dose PO x1 given 30-45min before anesthesia in pts 2-10 yo; Alt: 0.25-0.5 mg/kg/dose PO x1 given 60min before anesthesia in pts 2-5 yo

preop sedation, adult pts

[Possibly Effective]

Dose: 5 mg PO x1 given 90min before surgery; Alt: 10 mg PO x1 given night before surgery, then 10 mg PO x1 given 2h before surgery

preop sedation, peds pts

[Possibly Effective]

Dose: 0.5 mg/kg/dose PO x1 given 45min before surgery; Info: for pts 3-14 yo

prostate CA

[Insufficient Evidence]

Dose: 20 mg PO qpm

pruritus

[Insufficient Evidence]

Dose: 10 mg PO qhs

radiation dermatitis

[Insufficient Evidence]

Dose: apply emulsion cream topically bid; Alt: apply 25 mg cream topically bid; Info: use during radiation tx and 2-3wk after

REM sleep behavior disorder

[Insufficient Evidence]

Dose: 3 mg PO qhs

renal failure

[Insufficient Evidence]

Dose: 3 mg PO qd

sarcoidosis

[Insufficient Evidence]

Dose: 20 mg PO qd x1y, then 10 mg PO qd x1y

schizophrenia

[Insufficient Evidence]

Dose: 3-5 mg PO qpm

seasonal affective disorder

[Insufficient Evidence]

Dose: 0.25-2 mg PO qhs given 1-2h before desired bedtime

sepsis, adult pts

[Insufficient Evidence]

Dose: 50 mg PO qd; Alt: 60 mg IV x5 days; Info: used w/ standard tx

sepsis, peds pts

[Insufficient Evidence]

Dose: 20 mg PO x1; Info: used w/ standard tx for neonatal sepsis

smoking cessation

[Insufficient Evidence]

Dose: 0.35 mg PO x1 prn; Info: given 3.5h after smoking cessation

stress

[Insufficient Evidence]

Dose: 3 mg PO x1; Start: 1h before stress exposure

sunburn

[Possibly Effective]

Dose: apply 0.05-2.5% gel topically before UV exposure; Alt: apply 12.5% cream topically before UV exposure

tardive dyskinesia

[Insufficient Evidence]

Dose: 10 mg PO qd

temporomandibular disorder

[Possibly Effective]

Dose: 5 mg PO qhs

tension headache

[Insufficient Evidence]

Dose: 3 mg PO qhs

thrombocytopenia, chemo-related

[Possibly Effective]

Dose: 20-40 mg PO qpm; Start: 7 days before chemo, cont. through full tx course

tinnitus

[Insufficient Evidence]

Dose: 3 mg PO qhs

ulcerative colitis

[Insufficient Evidence]

Dose: 5 mg PO qhs; Alt: 3 mg PO qd

xerostomia

[Insufficient Evidence]

Dose: 20 mg PO qhs plus 10 mL of melatonin 0.2% oral gargle 15min before radiation